Skip to main content
Log in

Differences between99mTc-DTPA and99mTc-MAG3 captopril renographies in renovascular hypertension

  • Case Report
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Captopril renography (CRS) with99mTc-DTPA and99mTc-MAG3 was performed on a 21-year-old woman with renovascular hypertension due to right renal artery stenosis caused by fibromuscular dysplasia. In the affected kidney, the renogram pattern was substantially changed with99mTc-DTPA and99mTc-MAG3 following the administration of captopril, and the quantitated renal uptake indicating individual renal function was significantly decreased in99mTc-DTPA and slightly decreased in99mTc-MAG3. In the contralateral normal kidney, the renogram showed some minor changes with both radioagents, while the quantitated renal uptake was significantly decreased with99mTc-DTPA and substantially increased with99mTc-MAG3. The combined use of physiologically different renal agents99mTc-DTPA and99mTc-MAG3 is helpful in investigating hemodynamic and functional changes in the stenosed kidney as well as the normal kidney in RVH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sfukianakis GN, Jaffe DJ, Bourgoignie JJ, et al. Single dose captopril renography in diagnosis of renovascular hypertension.J Nucl Med 28: 1383–1392, 1987.

    Google Scholar 

  2. Mann SJ, Pickering TG, Sos TA, et al. Captopril renography in the diagnosis of renal artery stenosis: accuracy and limitations.Am J Med 90: 30–40, 1991.

    Article  PubMed  CAS  Google Scholar 

  3. Nally JV Jr, Black HR. State-of-the-art review: captopril renography-pathopysiological considerations and clinical observations.Semin Nucl Med 22: 85–97, 1992.

    Article  PubMed  Google Scholar 

  4. Fommei E, and the European Multicentre Study Group. Captopril radionuclide test in renovascular hypertension: a European multicentre study.Eur J Nucl Med 20: 617–623, 1993.

    Article  PubMed  CAS  Google Scholar 

  5. Elliot WJ, Martin WB, Murphy MB. Comparison of two noninvasive screening tests for renovascular hypertension.Arch Inter Med 153: 755–764, 1993.

    Article  Google Scholar 

  6. Meier GH, Sumpio B, Serato JF, Black HR, Gusberg RJ. Captopril renal scintigraphy: a new standard for predicting outcome after renal revascularization.J Vasc Surg 17: 280–287, 1993.

    Article  PubMed  CAS  Google Scholar 

  7. Shamlou KK, Drane WE, Hawkins IF, Fennell RS III. Captopril renography and the hypertensive renal transplantation patient: a predictive test of therapeutic outcome.Radiology 190: 153–159, 1994.

    PubMed  CAS  Google Scholar 

  8. Dondi M, Monetti N, Fanti S, Marchetta F, Cordelli C, Zagni P, et al. Use of technetium-99m-MAG3 for renal scintigraphy after angiotensin-converting enzyme inhibition.J Nucl Med 32: 424–428, 1991.

    PubMed  CAS  Google Scholar 

  9. Kahn D, Ben-Haim S, Bushnell DL, Madsen MT, Kirchner PT. Captopril-enhanced99mTcm-MAG3 renal scintigraphy in subjects with suspected renovascular hypertension.Nucl Med Comm 15: 515–528, 1994.

    Article  CAS  Google Scholar 

  10. Itoh K, Tsukamoto E, Nagao K, Nakada K, Kanegae K, Furudate M. Captopril renoscintigraphy with Tc-99m DTPA in patients with suspected renovascular hypertension: prospective and retrospective evaluation.Clin Nucl Med 18: 463–471, 1993.

    Article  PubMed  CAS  Google Scholar 

  11. Blaufox MD. Captopril renography, considerations in the selection of radiopharmaceuticals, provocative agents, and hypertensive subjects.Am J Hypertens 4: 675S-677S, 1991.

    PubMed  CAS  Google Scholar 

  12. Taylor A Jr, Martin LG. The utility of99mTc-mercaptoacetyltriglycine in captopril renography.Am J Hypertens 4: 731S-736S, 1991.

    PubMed  Google Scholar 

  13. Gates GF. Glomerular filtration rate: Estimation from fractional renal accumulation of99mTc-DTPA (stannous).Am J Roentgenol 138: 565–570, 1982.

    CAS  Google Scholar 

  14. Itoh K, Tsukamoto E, Kakizaki H, Nonomura K, Furudate M. Comparative study of renal scintigraphy with99mTcm- mercaptoacetyl-triglycine and123I-orthoiodohippurate.Nucl Med Comm 14: 644–652, 1993.

    Article  CAS  Google Scholar 

  15. Itoh K, Kato C, Shiga T. Expressing kidney uptake during99mTcm-MAG3 renography in terms of administered activity.Nucl Med Comm 16: 504–508, 1995.

    Article  CAS  Google Scholar 

  16. Pickering TG. Renovascular hypertension: etiology and pathophysiology.Semin Nucl Med 19: 79–88, 1989.

    Article  PubMed  CAS  Google Scholar 

  17. Lee H-B, Blaufox MD. Technetium-99m MAG3 clearances after captopril in experimental renovascular hypertension.J Nucl Med 30: 666–671, 1989.

    PubMed  CAS  Google Scholar 

  18. Miyamori I, Yasuhara S, Takedo Y, et al. Effects of converting enzyme inhibition on split renal function in renovascular hypertension.Hypertension 9: 415–421, 1986.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Itoh, K., Matsui, Y., Kato, C. et al. Differences between99mTc-DTPA and99mTc-MAG3 captopril renographies in renovascular hypertension. Ann Nucl Med 10, 251–255 (1996). https://doi.org/10.1007/BF03165401

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03165401

Key words

Navigation